Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06300307 · ClinicalTrials.gov registry record · Phase 1

Study of ATX-01 in Participants With DM1

A Phase 1 study of Myotonic Dystrophy 1, sponsored by ARTHEx Biotech S.L..

Recruiting
Registry status
Phase 1
Development phase
56
Enrollment target
12
Study locations

NCT06300307 is a Phase 1 study of Myotonic Dystrophy 1 that is actively recruiting participants, run by ARTHEx Biotech S.L.. The registered enrollment target is 56 participants, below the 1,099-participant average among 4 other Myotonic Dystrophy 1 trials with a reported enrollment target (95% lower). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06300307, a Phase 1 study of Myotonic Dystrophy 1, is actively recruiting participants, sponsored by ARTHEx Biotech S.L..

RECRUITING
Registry status
Phase 1
Development phase
56 participants
Enrollment target
12
Study locations

Study Summary

The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will receive three doses of ATX-01 or placebo. ATX-01 is a novel anti-miR (synthetic single stranded oligonucleotide) that inhibits a microRNA called miR-23b.

Conditions Studied

Myotonic Dystrophy 1

Interventions

  • DRUG Placebo
  • DRUG ATX-01

Study Locations (12)

Other

  • Institute of Myology - Paris
  • The NeMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan - Milan
  • Fondazione Policlinico A. Gemelli- IRCCS - Rome
  • Radboudumc - Nijmegen
  • Hospital Universitario Donostia - Donostia / San Sebastian
  • St. George's University Hospital - London

California

  • UCLA - Los Angeles

Florida

  • University of Florida - Gainesville

Iowa

  • University of Iowa Health Care - Department of Neurology - Iowa City

Kansas

  • University of Kansas Medical Center, Department of Neurology - Fairway

Virginia

  • Virginia Commonwealth University - Richmond

Quebec

  • Centre Intégré Universitaire de Santé et Services Sociaux du Saguenay-Lac-St-Jean - Chicoutimi

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2024-10-15
Est. Completion 2027-07
Phase Phase 1

Sponsor

ARTHEx Biotech S.L.

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06300307

The ClinicalTrials.gov registry entry for NCT06300307 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,099-participant average among 4 other Myotonic Dystrophy 1 trials with a reported enrollment target (95% lower). The listed sponsor is ARTHEx Biotech S.L., which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myotonic Dystrophy 1 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06300307 reports 12 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06300307 about?

NCT06300307 is a clinical study titled "Study of ATX-01 in Participants With DM1". The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending ...

What is the current status of trial NCT06300307?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2024-10-15. Estimated completion is 2027-07.

What conditions does trial NCT06300307 study?

This clinical trial studies the following conditions: Myotonic Dystrophy 1.

What interventions are being tested in trial NCT06300307?

The interventions under investigation include: Placebo (DRUG), ATX-01 (DRUG).

Who is sponsoring clinical trial NCT06300307?

This trial is sponsored by ARTHEx Biotech S.L., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06300307 being conducted?

This trial has 12 study locations across California, Florida, Iowa, Kansas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myotonic Dystrophy 1

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myotonic Dystrophy 1

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.